Keywords: trial, halted, poor, results, fmdc, matrix, pharmaceuticals

Trial halted on poor results with FMdC

Article | 11 October 1999

Print This

Matrix Pharmaceuticals has halted a Phase II clinical trial of itsnucleoside analog FMdC in non-small cell lung cancer patients, after ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in